EP2021499A4 - FUNCTIONAL NETWORKS FOR THE HIGH-FREQUENCY CHARACTERIZATION OF ELEMENTS REGULATING GENE EXPRESSION - Google Patents

FUNCTIONAL NETWORKS FOR THE HIGH-FREQUENCY CHARACTERIZATION OF ELEMENTS REGULATING GENE EXPRESSION

Info

Publication number
EP2021499A4
EP2021499A4 EP06849046A EP06849046A EP2021499A4 EP 2021499 A4 EP2021499 A4 EP 2021499A4 EP 06849046 A EP06849046 A EP 06849046A EP 06849046 A EP06849046 A EP 06849046A EP 2021499 A4 EP2021499 A4 EP 2021499A4
Authority
EP
European Patent Office
Prior art keywords
gene expression
regulating gene
functional networks
elements regulating
frequency characterization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP06849046A
Other languages
German (de)
French (fr)
Other versions
EP2021499A2 (en
Inventor
Nathan D Trinklein
Shelley F Aldred
Sara J Cooper
Richard M Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/636,385 external-priority patent/US20070161031A1/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of EP2021499A2 publication Critical patent/EP2021499A2/en
Publication of EP2021499A4 publication Critical patent/EP2021499A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EP06849046A 2005-12-16 2006-12-08 FUNCTIONAL NETWORKS FOR THE HIGH-FREQUENCY CHARACTERIZATION OF ELEMENTS REGULATING GENE EXPRESSION Ceased EP2021499A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75092905P 2005-12-16 2005-12-16
US76205606P 2006-01-24 2006-01-24
US11/636,385 US20070161031A1 (en) 2005-12-16 2006-12-07 Functional arrays for high throughput characterization of gene expression regulatory elements
PCT/US2006/046920 WO2007078599A2 (en) 2005-12-16 2006-12-08 Functional arrays for high throughput characterization of gene expression regulatory elements

Publications (2)

Publication Number Publication Date
EP2021499A2 EP2021499A2 (en) 2009-02-11
EP2021499A4 true EP2021499A4 (en) 2010-02-17

Family

ID=38228711

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06849046A Ceased EP2021499A4 (en) 2005-12-16 2006-12-08 FUNCTIONAL NETWORKS FOR THE HIGH-FREQUENCY CHARACTERIZATION OF ELEMENTS REGULATING GENE EXPRESSION

Country Status (3)

Country Link
EP (1) EP2021499A4 (en)
JP (1) JP2009519710A (en)
WO (1) WO2007078599A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135329A2 (en) 2009-05-18 2010-11-25 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
ES2707590T3 (en) * 2009-07-15 2019-04-04 Zhenglun Zhu Management of the treatment of inflammatory or autoimmune disorders using expression of Hom-1
KR20200047642A (en) 2010-04-23 2020-05-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
WO2011146411A1 (en) * 2010-05-17 2011-11-24 University Of Southern California Grp78 gene polymorphism rs391957 is associated with tumor recurrence and survival in gastrointestinal cancer patients
WO2012094560A2 (en) * 2011-01-07 2012-07-12 Applied Genetic Technologies Corporation Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
JP6482869B2 (en) * 2012-04-03 2019-03-13 国立研究開発法人国立成育医療研究センター DNA for controlling expression of miR-140 and method for screening drug using the DNA
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
WO2014031079A1 (en) * 2012-08-21 2014-02-27 Singapore Health Services Pte Ltd Method and/or probe for determining glaucoma susceptibility
JP6580027B2 (en) 2013-03-14 2019-09-25 モンサント テクノロジー エルエルシー Plant regulatory elements and uses thereof
EP3004872B1 (en) * 2013-06-04 2017-10-18 Virginia Commonwealth University Mda-9/syntenin promoter to image and treat metastatic cancer cells
SG11201605906UA (en) 2014-01-21 2016-08-30 Univ Bruxelles Muscle-specific nucleic acid regulatory elements and methods and use thereof
US20150276767A1 (en) * 2014-03-12 2015-10-01 The University Of Sydney Systems and methods for identifying cancers having activated progesterone receptors
EP3546594B1 (en) 2014-03-21 2020-12-23 Life Technologies Corporation Multi-copy reference assay
CN103981185B (en) * 2014-04-14 2016-04-27 浙江理工大学 Liver cancer-specific GP73 core promoter and screening construction process thereof
KR101791296B1 (en) 2014-04-17 2017-10-27 제주대학교 산학협력단 Expression cassette and vector with genes related Alzheimer's disease and transgenic cell line made from it
HK1246653A1 (en) 2014-11-17 2018-09-14 Context Biopharma Inc. Onapristone extended-release compositions and methods
CN104673797B (en) * 2015-02-09 2018-02-02 苏州大学 Participate in long-chain non-coding RNA and its application of human body cell ionising radiation stress reaction
WO2016149455A2 (en) * 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
WO2016200263A1 (en) * 2015-06-12 2016-12-15 Erasmus University Medical Center Rotterdam New crispr assays
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
EP3389632A4 (en) 2015-12-15 2019-11-06 Context Biopharma Inc. AMORPHOUS ONAPRISTONE-BASED COMPOSITIONS AND METHODS OF MAKING SAME
MY194135A (en) 2016-02-04 2022-11-14 Zhenglun Zhu Treatment and diagnosis of inflammatory disorders
WO2023150553A1 (en) * 2022-02-01 2023-08-10 University Of Rochester Gpr17 promoter-based targeting and transduction of glial progenitor cells
EP3452102B9 (en) 2016-04-15 2024-09-04 The Trustees of The University of Pennsylvania Gene therapy for treating hemophilia a
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
WO2018111104A1 (en) * 2016-12-14 2018-06-21 Erasmus University Medical Center Rotterdam Use of human crispr sequences in diagnostics
EP3600445A1 (en) * 2017-03-27 2020-02-05 Vrije Universiteit Brussel Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
EA201992358A1 (en) * 2017-04-03 2020-03-24 Инкоудид Терапьютикс, Инк. TISSELECTIVE EXPRESSION OF TRANSGEN
WO2018222792A1 (en) 2017-05-31 2018-12-06 The University Of North Carolina At Chapel Hill Optimized human clotting factor ix gene expression cassettes and their use
RU2671156C1 (en) * 2017-08-21 2018-10-29 Общество с ограниченной ответственностью "Центр Генетики и Репродуктивной Медицины "ГЕНЕТИКО" Method of preimplantation genetic diagnostics of type 1 spinal muscular atrophy
WO2019097122A1 (en) * 2017-11-20 2019-05-23 Turun Yliopisto A novel cip2a variant and uses thereof
JP7401432B2 (en) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス， インコーポレイテッド engineered DNA binding protein
AU2019227910B2 (en) 2018-02-28 2025-07-17 The Regents Of The University Of California A modular system for gene and protein delivery based on AAV
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
EP3856226B1 (en) 2018-09-28 2026-02-18 President and Fellows of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
EP3856260A1 (en) 2018-09-28 2021-08-04 President and Fellows of Harvard College Mutant reverse tetracycline transactivators for expression of genes
CA3116174A1 (en) * 2018-10-31 2020-05-07 Rutgers, The State University Of New Jersey Gramc: genome-scale reporter assay method for cis-regulatory modules
FR3088194B1 (en) 2018-11-09 2021-02-19 Univ Paris Sud USING THE MICRORNA MIR-27A-5P TO TREAT CLOSTRIDIUM DIFFICILE INTESTINAL INFLAMMATION
US20220073905A1 (en) * 2018-12-28 2022-03-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for single cell transcriptome-based development of aav vectors and promoters
WO2020205889A1 (en) 2019-04-01 2020-10-08 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
US20220170110A1 (en) * 2019-04-05 2022-06-02 Korea Advanced Institute Of Science And Technology Cancer diagnostic marker using transposase-accessible chromatin sequencing information about individual, and use thereof
KR102192455B1 (en) * 2019-04-05 2020-12-17 한국과학기술원 A cancer diagnosis marker based on ATAC-Seq and Method using the same
WO2020243651A1 (en) 2019-05-29 2020-12-03 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation
CN110117659B (en) * 2019-06-18 2022-10-11 上海奕谱生物科技有限公司 Novel tumor marker STAMP-EP10 and application thereof
WO2021234455A2 (en) * 2020-05-19 2021-11-25 Ixaka France Promoter sequences for in vitro and in vivo expression of gene therapy products in cd3+ cells
CA3163572A1 (en) 2020-05-27 2021-12-02 Oleksandr PASTUKHOV Novel transduction enhancers and uses thereof
CN116391230A (en) * 2020-08-21 2023-07-04 瑞泽恩制药公司 Methods and systems for sequence generation and prediction
WO2022049295A1 (en) * 2020-09-07 2022-03-10 Centre National De La Recherche Scientifique Eukaryotic dna replication origins, and vector containing the same
JP7415042B2 (en) * 2020-10-09 2024-01-16 テナヤ セラピューティクス， インコーポレイテッド Plakophilin 2 gene therapy methods and compositions
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
US11464872B2 (en) * 2020-12-07 2022-10-11 Noga Therapeutics Ltd. Lentiviral vectors for therapeutic expression of BTK in haematopoietic cells
US20240173436A1 (en) * 2021-03-31 2024-05-30 Hunterian Medicine Llc Compact promoters for gene expression
CN113265428B (en) * 2021-06-11 2023-03-14 东北林业大学 Detection system for constructing copper change in living cells by utilizing metallothionein and application
CN119654412A (en) * 2022-06-27 2025-03-18 中美瑞康核酸技术(南通)研究院有限公司 Oligonucleotide modulators that activate complement factor H expression
WO2024110770A1 (en) * 2022-11-22 2024-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) A new promoter for retinal pigment epithelium (rpe) targeted gene therapy
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy
WO2025171086A1 (en) * 2024-02-07 2025-08-14 Asimov Inc. Promoters and uses thereof
WO2026030244A1 (en) * 2024-07-30 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200760B1 (en) * 1997-02-24 2001-03-13 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242211B1 (en) * 1996-04-24 2001-06-05 Terragen Discovery, Inc. Methods for generating and screening novel metabolic pathways
US6504084B1 (en) * 1999-04-23 2003-01-07 Pioneer Hi-Bred International, Inc. Maize NPR1 polynucleotides and methods of use
US20030211481A1 (en) * 2002-05-08 2003-11-13 Erives Albert J. Method for identifying cellular targets

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200760B1 (en) * 1997-02-24 2001-03-13 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COOPER SARA J ET AL: "Comprehensive analysis of transcriptional promoter structure and function in 1% of the human genome.", GENOME RESEARCH JAN 2006, vol. 16, no. 1, 12 December 2005 (2005-12-12), pages 1 - 10, XP009126140, ISSN: 1088-9051 *
ENCODE PROJECT CONSORTIUM: "The ENCODE (ENCyclopedia Of DNA Elements) Project.", SCIENCE (NEW YORK, N.Y.) 22 OCT 2004, vol. 306, no. 5696, 22 October 2004 (2004-10-22), pages 636 - 640, XP009126138, ISSN: 1095-9203 *
KIM TAE HOON ET AL: "Direct isolation and identification of promoters in the human genome.", GENOME RESEARCH JUN 2005, vol. 15, no. 6, June 2005 (2005-06-01), pages 830 - 839, XP002412922, ISSN: 1088-9051 *
TRINKLEIN NATHAN D ET AL: "An abundance of bidirectional promoters in the human genome.", GENOME RESEARCH, vol. 14, no. 1, January 2004 (2004-01-01), pages 62 - 66, XP009126141, ISSN: 1088-9051 *
TRINKLEIN NATHAN D ET AL: "Identification and functional analysis of human transcriptional promoters.", GENOME RESEARCH FEB 2003, vol. 13, no. 2, February 2003 (2003-02-01), pages 308 - 312, XP009126139, ISSN: 1088-9051 *
WILSON V S ET AL: "A NOVEL CELL LINE, MDA-KB2, THAT STABLY EXPRESSES AN ANDROGEN- AND GLUCOCORTICOID-RESPONSIVE REPORTER FOR THE DETECTION OF HORMONE RECEPTOR AGONISTS AND ANTAGONISTS", TOXICOLOGICAL SCIENCES, ACADEMIC PRESS, SAN DIEGO, FL, US, vol. 66, no. 1, 1 March 2002 (2002-03-01), pages 69 - 81, XP009028294, ISSN: 1096-6080 *

Also Published As

Publication number Publication date
WO2007078599A8 (en) 2008-10-30
WO2007078599A2 (en) 2007-07-12
WO2007078599A9 (en) 2007-10-04
EP2021499A2 (en) 2009-02-11
WO2007078599A3 (en) 2008-08-28
JP2009519710A (en) 2009-05-21

Similar Documents

Publication Publication Date Title
ZA200702976B (en) Polymorphic forms of 6-[2-(methylcarbamoyl)phenyl-sulfanyl]-3-E-[2-(pyrldin-2-yl)ethenyl]indazole
IL197420A0 (en) Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-
ZA200709897B (en) Improved methods controlling gene expression
IL180017A0 (en) Amino-5, 5-diphenylimidazolone derivatives for the inhibition of beta-secretase
IL190608A0 (en) 5-(arylsulfonyl)-pyrazolopiperidines
DE602005022650D1 (en) Improved plating process
EP1972612A4 (en) NEW POLYMERIZABLE COMPOUNDS
EP2081698A4 (en) CRIBLE FOR VIBRANT SEPARATOR
ZA200703436B (en) Methods for increasing maize yields
PL2035357T3 (en) Process for the manufacture of 1,2-dichloroethane
DE602007012247D1 (en) PRODRUGS OF 5-AMINO-3- (3'-DEOXY-BETA-D-RIBOFURANOSYL) -THIAZOLA4,5-DUPRYIDIN-2,7-DION
IL227950A0 (en) Polymorphs and amorphous forms of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1h-pyrazole-3-carbonitrile
DK1924574T3 (en) Process for the Synthesis of 5- (Methyl-1H-imidazol-1-yl) -3- (trifluoromethyl) -benzenamine
FR2931845B1 (en) PRODUCTION OF A BIOFILM ON AN ELECTRODE FOR BIOPILE, ELECTRODE AND BIOPILE OBTAINED.
ZA200903981B (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy-3-bromo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethyl-benzamide
PL1896425T3 (en) Process for the synthesis of 5- (methyl- 1h-imidazol-1-yl) -3- (trifluoromethyl) -benzeneamine
ATE453640T1 (en) MICROBICIDAL SILYLATED CARBOXAMIDES
IL187735A0 (en) 2-(n-nethyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
PL1848678T3 (en) Process for the preparation of intermediates
EP2217721A4 (en) GENE THERAPY FOR OSTEOARTHRITIS
FR2912476B3 (en) ASSEMBLY PIECE FOR LONGIFORM ELEMENTS, AND METHOD OF MANUFACTURING THE ASSEMBLY PART
EP1873240A4 (en) GENE OF REGULATION OF THE EXPRESSION OF THE GENE hTERT
FR2917963B3 (en) PROSTHETIC ASSEMBLY FOR THE ARTICULATION OF THE SHOULDER.
FR2889177B1 (en) HEART MATERIAL FOR TUBULURE.
EP1805152A4 (en) Insecticidal 3-(dihaloalkenyl) phenyl derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080715

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20100115

17Q First examination report despatched

Effective date: 20100421

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120618